Publications by authors named "David Altarac"
Article Synopsis
- - The study compared the effectiveness and safety of sulbactam-durlobactam versus colistin in treating carbapenem-resistant complex (CRABC) infections, focusing on both monomicrobial and polymicrobial cases using a combination with imipenem-cilastatin.
- - Clinical outcomes showed that sulbactam-durlobactam performed similarly in both infection types, while colistin resulted in higher mortality for monomicrobial infections.
- - The findings indicate that sulbactam-durlobactam could potentially improve treatment outcomes for polymicrobial CRABC infections, especially as it restored imipenem susceptibility in many cases, but more clinical evidence is needed for confirmation.
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Lancet Infect Dis
September 2023
Article Synopsis
- - The study investigates the effectiveness and safety of sulbactam-durlobactam compared to colistin in treating serious infections caused by carbapenem-resistant Acinetobacter baumannii, in a phase 3 randomized trial involving 181 patients.
- - Patients were treated with either sulbactam-durlobactam or colistin, both alongside imipenem-cilastatin, with the main goal of assessing 28-day overall survival and safety regarding kidney toxicity.
- - Conducted across 59 clinical sites globally, the trial aimed to determine if sulbactam-durlobactam was as effective as colistin, providing critical data in combating multidrug-resistant bacterial infections.
Article Synopsis
- There’s a growing need for new antibiotics to combat antimicrobial resistance, especially against tough gram-negative bacteria like Acinetobacter baumannii.* -
- Sulbactam-durlobactam (SUL-DUR) is a promising antibiotic designed to specifically target drug-resistant strains of ABC and has shown positive results in the ATTACK trial, which compared its effectiveness to colistin.* -
- SUL-DUR not only met the key effectiveness goal but also demonstrated a better safety profile, suggesting it could become a crucial treatment for serious infections caused by resistant ABC strains if approved.*
The use of antibiotics directly correlates with the increase in antimicrobial resistance (AMR). Targeting novel antibiotics to patients with multidrug-resistant (MDR) pathogens should enhance their durability and slow development of resistance. The discovery, development, and clinical adoption of pathogen-targeted antibiotics have been hampered by technical and regulatory challenges.
View Article and Find Full Text PDF